Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220817 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
A Phase 2 study, sponsored by POM Wonderful.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01220817: Completed Phase 2 study, sponsored by POM Wonderful.
NCT01220817 is a Phase 2 study that has completed, run by POM Wonderful. The registered enrollment target is 104 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01220817, a Phase 2 study, has completed, sponsored by POM Wonderful.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tolerated.
Primary Outcome
All subjects who have a baseline PSA value and at least 1 on study PSA value. The PSADT will be calculated as ln 2 (0.693)/ β (slope of the linear regression fit to ln PSA vs. time in months).
Interventions
- DRUG 3 POMx capsules
- DRUG 1 POMx capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT01220817 record still lists
NCT01220817 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which 3 POMx capsules is the first listed.
NCT01220817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01220817 about?
NCT01220817 is a clinical study titled "Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study". When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tole...
What is the current status of trial NCT01220817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2007-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01220817?
The interventions under investigation include: 3 POMx capsules (DRUG), 1 POMx capsule (DRUG).
Who is sponsoring clinical trial NCT01220817?
This trial is sponsored by POM Wonderful, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01220817's enrollment target sits among peer trials
104 660th of 2000 higher than 1,337 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia